Seeking Alpha

ImmunoGen (IMGN +1.8%) says it's amended its multi-target agreement with Novartis (NVS -0.6%),...

ImmunoGen (IMGN +1.8%) says it's amended its multi-target agreement with Novartis (NVS -0.6%), which was originally entered into in October, 2010. As a result, IMGN is eligible to receive a $1M upfront fee and the opportunity to receive milestone payments potentially totaling approximately $200M or $238M, depending on the composition of any resultant products.
Comments (1)
  • mstar913
    , contributor
    Comments (2) | Send Message
     
    I don't recall Novartis having any products in the pipe line, so maybe this is simply the price of a contract termination, but designed to look like a modification with future significance.
    4 Apr 2013, 05:48 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs